On Friday, October 5, 2018, FMD has successfully hosted a webinar titled "Leverage the Favorable Regulatory Reforms in China to Accelerate Global Drug Development Programs." Dr. Dan Zhang, Executive Chairman of FMD, and Emil Fu, SVP International Intergration of FMD, discussed the regulatory reform in China and the strategies biopharm companies can take to make your programs more efficient.
In this webinar we presented:
- The impact of the recent regulatory reform in China.
- The potentials to leverage favorable changes to accelerate global drug development programs.
If you missed the opportunity to join us that day but are still interested in discovering how to leverage the favorable regulatory reforms in china to accelerate global drug development programs, please click on the links below to review the recording, slides.
FMD is a China-based clinical CRO with global footprint, in Asia, US, and Europe. We provide full suite of clinical, regulatory and medical services. Since the founding of FMD in 2007, we strive to provide ICH-compliant services to global clients.
At FMD we have been receiving many requests from clients on entry strategy to China and clinical implementations in the country. Developers large and small are eager to take advantage of the friendlier regulatory regimes in China. FMD has been helping many clients from strategic development, clinical operations, to regulatory filing. Your company may benefit from faster development cycle, shareable datasets, and faster market penetration.